#United States #San Diego #biopharmaceuticals #Viking Therapeutics #VKTX

Viking Therapeutics to Attend Major Investor Conferences in April 2026

Viking Therapeutics, Inc. is poised to make a significant presence at two pivotal investor conferences this April, underscoring its dedication to advancing treatments for metabolic and endocrine disorders. As a clinical-stage biopharmaceutical company, Viking is focused on developing novel therapies that can enhance patient outcomes in these critical areas.

Conference Participation Details

Viking's management will engage in one-on-one meetings at the following conferences:

1. Raymond James Biotech/BioPharma Conference 2026
- Date: April 14, 2026
- Location: New York, NY
- This conference is a platform where biotechnology and pharmaceutical leaders converge to discuss advancements in the field, offering Viking an opportunity to showcase its innovative pipeline.

2. Piper Sandler Spring Biopharma Symposium 2026
- Date: April 16, 2026
- Location: Boston, MA
- At this symposium, Viking will further highlight its groundbreaking research and development efforts.

About Viking Therapeutics, Inc.

Founded with a vision to combat metabolic and endocrine disorders, Viking Therapeutics is dedicated to creating first-in-class or best-in-class therapeutic options. The company is at the forefront of innovation, leveraging its in-depth understanding of metabolic pathways to design therapies that not only advance medical science but also significantly improve the lives of patients.

Among its flagship projects is VK2735, a novel dual agonist targeting glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This therapy is currently under evaluation in a Phase 3 obesity program that consists of two pivotal trials—VANQUISH-1 and VANQUISH-2. Initial data from earlier trials indicate a promising safety and tolerability profile, along with early signs pointing towards its effectiveness in treating obesity.

In addition, Viking is exploring an oral formulation of VK2735, further expanding its therapeutic reach. Another exciting development is VK2809, an orally active selective thyroid hormone receptor beta agonist. This compound has shown significant potential in addressing lipid and metabolic disorders, achieving positive results in clinical trials aimed at conditions such as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Viking Therapeutics is also innovating in the rare disease domain, particularly focusing on VK0214, which is under investigation for X-linked adrenoleukodystrophy (X-ALD). Early trial results are encouraging, indicating safety and favorable effects on plasma fatty acid levels in patients.

A Commitment to Innovation

Viking's participation in these upcoming investor conferences not only emphasizes its current achievements but also its enduring commitment to developing transformational therapies. By connecting with investors, Viking aims to bolster support for its ongoing clinical programs and its ambitious vision for the future of metabolic health.

As Viking Therapeutics continues its journey to reshape treatment paradigms for metabolic and endocrine disorders, stakeholders can look forward to insightful updates from these conferences, shedding light on the future direction of the company and its promising therapeutic candidates.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.